Cookie Settings
 
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Is it time for women visiting your practice to consider a LARC?

Current LARCs available:

The list of LARCs presented is not exhaustive. Direct comparisons cannot be made between the LARCs presented owing to a lack of head-to-head studies. Please refer to the individual Summary of Product Characteristics/ prescribing information for full details

LARC: long-acting reversible contraceptive

*These percentages are estimates from the USA.6 “Typical use effectiveness” is how effective the method is with an average person. This tends to reflect real life usage (including inconsistent and incorrect use). “Perfect use effectiveness” is how effective the method is when used perfectly.8 Refer to the Summary of Product Characteristics/ prescribing information for “perfect” use.

†It is strongly recommended that NEXPLANON® be inserted and removed only by healthcare professionals who have completed training for the use of the NEXPLANON® applicator and techniques for insertion and removal of the NEXPLANON® implant, and, where appropriate, that supervision be requested prior to inserting or removing the implant.1

‡Pregnancies have occurred as early as 14 weeks after a preceding injection, however, in clinical trials, the mean time to return of ovulation was 5.3 months following the preceding injection.7

§Cumulative pregnancy rates for IUDs with copper content >300 mm2 are noted as being between 0.1% and 1% after the first year of use.2

¶The failure rate (Pearl Index) was approximately 0.2% at 1 year and the cumulative failure rate was approximately 0.7% at 5 years. The failure rate also includes pregnancies due to undetected expulsions and perforation.5

References

  1. NEXPLANON® Summary of Product Characteristics
  2. The Faculty of Sexual & Reproductive Healthcare. Clinical guidance: intrauterine contraception, clinical effectiveness unit, amended September 2019. Available at: fsrh.org. Accessed September 2021
  3. NHS. Intrauterine device (IUD), last reviewed March 2021. Available at: nhs.uk. Accessed September 2021
  4. The Faculty of Sexual & Reproductive Healthcare. Clinical guidance: progestogen-only implant, clinical effectiveness unit, February 2021. Available at: fsrh.org. Accessed September 2021
  5. Mirena Summary of Product Characteristics
  6. The Faculty of Sexual & Reproductive Healthcare. Clinical guidance: progestogen-only injectable contraception, clinical effectiveness unit, amended October 2020. Available at: fsrh.org. Accessed September 2021
  7. Depo-Provera Summary of Product Characteristics
  8. Contraceptive Match. Welcome to Contraceptive Match, July 2020. Available at: https://www.contraceptivematch.co.uk. Accessed September 2021

GB-XPL-11009 | Date of preparation: September 2021

GB-XPL-115073 | Date of preparation: September 2021